Read by QxMD icon Read


Francesco Locatelli, Lucia Del Vecchio, Maria Carmen Luise
Erythropoiesis-stimulating agents (ESAs) are not perfect, since they have potential side effects. Iron therapy is also receiving growing attention in recent years. Areas covered: We performed a literature search on PubMed using the following key words: anemia, chronic kidney disease, HIF stabilisers, sotatercept, actin traps, iron, iron-containing phosphate binders, iron dialysate. We reviewed new drugs that are under clinical development to obtain better safety and activity and/or easier and cheaper manufacturing processes in comparison to available ESAs...
June 2017: Expert Opinion on Pharmacotherapy
Domenico Santoro, Maria Teresa Ingegnieri, Giuseppe Vita, Silvia Lucisano, Carmelo Zuppardo, Valeria Canale, Vincenzo Savica, Michele Buemi
BACKGROUND: Hyperphosphoremia is one of the most important risk factors for morbidity and mortality for chronic kidney disease (CKD) patients, and also, for the general population. Excessive dietary intake of phosphate (P) is one of the key factors. In particular, P in its inorganic form, which is contained in food additives, is more readily absorbed. Unfortunately, these food additives are mostly present in convenience so called "fast foods" (pre-cooked), soft drinks, which represent the typical food consumed by our hemodialysis (HD) population, composed by elderly people, mostly low-socio economic class, who often live alone...
July 2015: Nephro-urology Monthly
M Ndiaye, T Dehanin, A-D Sow, M-S Sène, A-M Basse, A-L Fall, L-B Seck, K Touré, A-G Diop, H-D Sow, M-M Ndiaye
Congenital hypomagnesemia is a rare disease, with an impact on cognitive and neurological development. We report on three familial cases of congenital hypomagnesemia, two boys and one girl who belong to the same consanguineous family. They all presented neonatal seizures and a psychomotor developmental delay. Cerebral computed tomography showed cerebral atrophy and calcifications in one case and magnetic resonance imaging found predominant cerebellar atrophy in the two other cases. All three patients also had hypocalcemia, hyperphosphoremia, and hypomagnesemia...
November 2013: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
S El Hechmi, S Bouhlel, W Melki, Z El Hechmi
UNLABELLED: Fahr's syndrome is a rare disorder characterized by abnormal deposits of calcium in areas of the brain that control movement, including the basal ganglia and the cerebral cortex associated with many neurological and psychiatric abnormalities such as a rigid hypokinetic syndrome, mood disorders and cognitive impairment. Fahr's syndrome is secondary to some disorders, such as hypoparathyroidism. CASE REPORT: We report the case of a 56 year-old man, with a history of cataract, who was admitted to our psychiatric hospital for the first time in his life because of psychotic symptoms associated with irritability and aggressiveness...
June 2014: L'Encéphale
L M Lou, A Caverni, J A Gimeno, R Moreno, J Pérez, R Alvarez, B Campos, M García, A Gutiérrez, S Bielsa, J Castilla, A Sanz, F Martin
BACKGROUND: Elevated serum phosphorus has been identified as a cardiovascular risk factor. This study aimed to assess the effectiveness of dietary intervention to reduce phosphorus intake and to improve the calcium-phosphorus metabolism in hemodialysis patients. DESIGN: Patients were included in a 6-month, 2-group experimental study if their previous 3-month average serum phosphorus was over 5.5 mg/dl. Patients were allocated to intensive dietary intervention or usual dietary recommendations...
June 2012: Clinical Nephrology
Clotilde Muller, Sandrine Muller, Aicha Sissoko, Alexandre Klein, Bernadette Faller, Francois Chantrel
Lanthanum therapy is an efficient therapy of hyperphosphoremia by chelating phosphore in the digestive tract. Lanthanum is a silvery white metallic element that belongs to group 3 of the periodic table. This drug is lightly absorbed and has low water solubility. It should be borne in mind that abdominal X-rays of patients taking lanthanum carbonate may have a radio-opaque appearance typical of imaging agents. This characteristic is suggested to confirm adherence of the patient by doing an abdominal X-ray. We describe in our case a particular good compliant patient with slow digestive transit, which ends by pseudo-occlusion...
October 2012: Hemodialysis International
Yiyan Liu
Superscans on bone scintigraphy have been described mostly in metastatic and metabolic bone diseases, with different patterns and appearances of radiotracer uptake. This is a report of bone scintigraphy demonstrating superimposed metastatic and metabolic superscan in a patient with prostate cancer, who subsequently developed renal osteodystrophy. Two years after the first bone scintigraphy showing multiple metastases, the patient developed renal insufficiency, hyperphosphoremia, and hypocalcemia. Repeat bone scintigraphy demonstrates significantly different appearance from that of the first study...
March 2011: Clinical Nuclear Medicine
Pilar Segura Torres, F J Borrego Utiel, M C Sánchez Perales, M J García Cortés, M M Biechy Baldán, V Pérez Bañasco
BACKGROUND: Treatment of secondary hyperparathyroidism with cinacalcet improves control of PTH, phosphorus, calcium and Ca x P product, enabling to achieve targets recommended by K/DOQI guidelines for PTHi in only 30-50% of patients, in studies with a very selected population. The aim of this study was to analyze its effectiveness in real clinical practice, comparing results with targets recommended by K/DOQI and KDIGO guidelines and to investigate factors having influence on PTH responsiveness to cinacalcet...
2010: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
Hayet Kaaroud, Soumaya Béji, Inés Souissi, Fethi Ben Hamida, Karim Zouaghi, Fatma Ben Moussa, Fethi El Younsi, Ezzedine Abderrahim, Taieb Ben Abdallah, Hédi Ben Maiz, Adel Kheder
BACKGROUND: Calciphylaxis is a small vessel disease responsible for vascular calcification and skin necrosis. It occurs in association with chronic renal failure and has a poor prognosis. BUT: Report new cases. We report 3 cases of calciphylaxis occurred in patients with chronic renal failure secondary to interstitial nephritis in 1 case, diabetic nephropathy in 1 case and thrombotic microangiopathy in 1 case. CASES: They were 2 females an 1 man aged of 44, 3 years meanly...
April 2010: La Tunisie Médicale
Vincenzo Savica, Lorenzo A Calò, Paolo Monardo, Domenico Santoro, Agostino Mallamace, Ugo Muraca, Guido Bellinghieri
BACKGROUND: Hyperphosphatemia provides relevant and dangerous evidence of end-stage renal disease (ESRD) in patients undergoing periodic hemodialysis. The relationship between hyperphosphatemia and cardiovascular calcification, with the consequences of high morbidity and mortality after cardiovascular events, is well-defined. Hyperphosphatemia is treated by dietary limitation of phosphorus ingestion and by phosphate binders, but only half of ESRD patients fall within the range of K/DOQI guidelines...
January 2009: Journal of Renal Nutrition
V Lorenzo Sellares
Mineral metabolism abnormalities in chronic kidney disease (CRK) have adverse effects, particularly on the skeleton and cardiovascular system. Among the classic biochemical abnormalities, hyperphosphoremia plays a significant role. It stimulates parathyroid hormone production by the parathyroid gland both directly (it increases PTH synthesis and secretion and induces cell proliferation) and indirectly (it suppresses calcitriol synthesis by the kidneys and reduces vitamin D receptor and calcium sensor expression)...
2008: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
J C Herrero, A Molina, C Lentisco, C García, M Ortiz, C Mon, O Ortega, I Rodríguez, A Oliet, A Vigil, P Gallar
UNLABELLED: Sclerosing Encapsulating Peritonitis (SEP) is a rare but serious complication of continuous ambulatory peritoneal dialysis (CAPD) with a high morbi-mortality. We describe our experience with patients was diagnostic of SEP, their characteristics in CAPD and their clinic evolution after diagnosis. 190 CAPD patients were follow-up during 17 years. Eight patients (4.2%) developed SEP. Average age 45+/-14 years (range 29-64 years), four was male. Time in CAPD was 72+/-29 months (range 24-120 months)...
2007: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
V Savica, L A Calò, A Granata, R Caldarera, A Cavaleri, D Santoro, P Monardo, R Savica, U Muraca, G Bellinghieri
AIMS: Hyperphosphoremia, main contributor to cardiovascular calcifications, has a major impact on the morbidity and mortality of chronic renal failure (CRF) patients. Phosphate binders and dietary phosphate limitation are not effective enough to abolish hyperphosphoremia-induced cardiovascular abnormalities, therefore, the identification of other and more timely approaches for serum phosphorous reduction is necessary. Salivary fluid contains phosphate which, if related to the daily salivary secretion (1,000 - 1,800 ml), deserves attention as a marker for an earlier start of pharmacologic treatment for phosphorous removal...
October 2007: Clinical Nephrology
María D Arenas, Fernando Alvarez-Ude, Vicente Torregrosa, María T Gil, María A Carretón, Analía Moledous, Carlos Nuñez, Ramón Devesa, Begoña Albiach
BACKGROUND: After application of K/DOQI recommendations, a large proportion of our patients failed to reach the proposed targets. This study examined the causes of these findings. METHODS: Patients (n=163) were compared in 2 periods (8 months before and after application of K/DOQI guidelines). Serum calcium (Ca), phosphorus (P), parathyroid hormone (PTH) and calcium x phosphate product (Ca x P); mean dialysate Ca content; mean doses of vitamin D; and average prescription of Ca-based phosphate binders and sevelamer in both periods were analyzed...
July 2007: Journal of Nephrology
P Delanaye, L Van Overmeire, B E Dusbois, J M Krzesinski
Disorders of the phosphocalcic metabolism are frequent in dialysis patients. Such disorders are difficult to treat and have negative impact on bone health, but also on cardiovascular mortality. Hyperphosphoremia is a strong predictor of cardiovascular mortality. New phosphate binders are now available in Belgium. A new molecule acting on the calcium receptor of the parathyroid glands is able to control secondary and tertiary hyperparathyroidism in dialysis patients. These new therapies, specific for dialysis patients, will be reviewed in this article...
May 2007: Revue Médicale de Liège
Laura Bertolini, Umberto Maggiore, Giorgio Savazzi
The next decade will face an increase in the number of patients affected by end-stage renal disease. In line with the growing incidence of type 2 diabetes, hypertension and old age in the general population, we can expect a dramatic increase of uremic patients needing a substitutive treatment of renal function. On the basis of the current trends, we expect an exponential growth of cardiovascular complications in both dialysis and transplant populations. Progress in the treatment of end-stage renal disease will aim at the prevention of cardiovascular complications, that remain the leading cause of morbidity and mortality in uremic patients...
December 2006: Recenti Progressi in Medicina
F Rivera, M D Sánchez de la Nieta, R Echarri, S Anaya, A Carreño, M C Vozmediano, M P Alcaide
BACKGROUND: The publication in 2003 of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommended targets levels for serum iPTH, Ca, P, and CaxP product. However, many patients do not achieved these target ranges. It is necessary to known the percentage of patients out of range in order to prevent the development of bone disease and to reduce mortality and morbidity. OBJECTIVES: To know the degree of control of Ca-P metabolism in haemodialysis patients in our haemodilalysis facilities and the achievement of target levels recommended by K/DOQI Guidelines...
2006: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
Jun'ichiro Hamada, Kazuya Tamai, Wataru Ono, Koichi Saotome
OBJECTIVE: Extraskeletal calcifications generally develop in uremic patients. Periarticular massive calcifications, referred to as uremic tumoral calcinosis (UTC), represent solitary or multifocal calcium phosphate deposits. Our objectives were to clinically analyze a series of 8 patients with UTC undergoing hemodialysis, and to characterize calcium deposits in UTC. METHODS: The clinical, radiological, and pathological features of 8 consecutive patients (4 men and 4 women, mean age 49 yrs) with UTC were analyzed, and treatment and outcome were evaluated...
January 2006: Journal of Rheumatology
Francisco Maduell, Jose L Gorriz, Luis M Pallardo, Ramon Pons, Carlos Santiago et al.
AIM: The objective of the study was to determine the situation concerning mineral metabolism and bone disease in hemodialysis (HD) patients living in the community of Valencia (Spain), as well as the clinical practices for bone disease control in relation to the laboratory targets recommended in the National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) guidelines. METHODS: In December 2003, a cross-sectional study was performed including 2392 patients (1485 males and 907 females) from 43 different centers in the council of Valencia (the entire HD population)...
November 2005: Journal of Nephrology
Joan Fort
The risk of developing cardiovascular disease is greatly increased in patients undergoing renal replacement therapy and, notably, morbidity and mortality due to therapy is much higher in these patients than in the general population. Minimal alterations in renal function, as evidenced by reduced glomerular filtration rate and the presence of albuminuria, have been described as potent cardiovascular risk factors. The classic risk factors only partly explain this difference; hence, we must admit the existence of known and emerging factors associated with increased cardiovascular risk in patients with renal disease...
December 2005: Kidney International. Supplement
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"